Calcium channel blockers in older patients show 70% greater risk of cancer -- Pahor study.
CALCIUM ANTAGONISTS SHOW 70% GREATER CHANCE OF CANCER DEVELOPMENT in older patients than in patients not taking calcium channel blockers, according to the results of a study published in the Aug. 24 issue of the Lancet by Marco Pahor, et al., University of Tennessee-Memphis. The authors suggest that a possible mechanism for the link between CCBs and cancer is that calcium antagonists "inhibit apoptosis in various experimental models," thereby possibly interfering with the prevention of cancer.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth